Loading people...
Douglas Crawford is the Managing General Partner at Mission BioCapital and the General Manager of MBC BioLabs, based in San Francisco, California. He previously served as Associate Director at the California Institute for Quantitative Biosciences at UCSF, where he established the university's first technical incubator. As an entrepreneur, Crawford co-founded Allopartis Biotechnologies, an early-stage life sciences startup that was acquired by Novozymes in 2013. Through MBC BioLabs, he has hosted over 400 early-stage companies that have collectively raised $20 billion and advanced 173 distinct drug programs. At Mission BioCapital, he oversees a portfolio of 40 to 45 investments, including Caribou and Principia Biopharma, and helped close the firm's $275 million Fund V in 2021. Crawford leverages his doctorate in biochemistry to focus his career on seed-stage biopharmaceutical investments and the operational development of biotech infrastructure.
Douglas Crawford stands as a pivotal figure in the life science venture capital landscape, serving as a Managing Partner at Mission BioCapital. In this crucial role, he spearheads the firm's investment strategy, meticulously identifying and nurturing groundbreaking early-stage biotechnology and healthcare companies. His leadership is instrumental in guiding Mission BioCapital's mission to fund transformative scientific innovations that address significant unmet medical needs across various therapeutic areas.
Mission BioCapital, under Crawford's guidance, focuses intently on the nascent stages of company development. The firm's investment thesis centers on ventures with robust scientific foundations, often emerging from leading academic institutions. Douglas Crawford's expertise spans a broad spectrum of life science sectors, including novel therapeutics, advanced diagnostics, innovative medical devices, and cutting-edge digital health solutions. He is particularly adept at recognizing the potential in companies poised to revolutionize patient care and improve human health outcomes.
Crawford's distinguished career background provides a strong foundation for his success in venture capital. Holding a Ph.D. in Biochemistry from the University of California, Berkeley, and having completed postdoctoral research at the University of California, San Francisco, he possesses a deep understanding of scientific discovery and its translation into commercial applications. Prior to his current role, Douglas Crawford served as a Managing Director at the California Institute for Quantitative Biosciences (QB3), where he played a key role in fostering entrepreneurship and company formation within the academic ecosystem. He was also a co-founder of Mission Bay Capital, the predecessor to Mission BioCapital, further solidifying his long-standing commitment to early-stage life science investment.
His extensive experience includes not only evaluating scientific merit but also actively participating in the incubation and strategic development of portfolio companies. While specific individual "notable investments" are often attributed to the firm as a whole, Douglas Crawford has been deeply involved in shaping Mission BioCapital's impressive portfolio. This portfolio includes companies developing innovative treatments for oncology, neurological disorders, rare diseases, and infectious diseases, among others. His strategic insights and hands-on approach help guide these promising ventures from concept to clinical impact, driving both scientific progress and investor returns. Douglas Crawford's dedication to fostering innovation makes him a highly respected and influential leader in the biotechnology investment community.
Douglas Crawford is a Managing Partner at Mission BioCapital, a prominent venture capital firm focused on early-stage life science investments. He is known for his deep scientific background and expertise in biotechnology.
Douglas Crawford primarily invests in early-stage life science companies through Mission BioCapital. His focus areas include novel therapeutics, advanced diagnostics, innovative medical devices, and digital health solutions, particularly those with strong scientific foundations.
Douglas Crawford works as a Managing Partner at Mission BioCapital, a leading venture capital firm dedicated to funding transformative innovations in the life sciences sector.
